Stevanato Group Says Liraglutide-Based Combination Products Incorporating Its Proprietary Alina Pen Injector Platform Receives Marketing Authorizations In Europe

The regulatory approvals cover therapies for diabetes and weight management, further expanding the commercial adoption of Stevanato Group's proprietary Alina® pen injector platform across Europe.

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders.